Profile for Canada Patent: 2906580

US Patent Family Members and Approved Drugs for Canada Patent: 2906580

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
10,080,733	Sep 20, 2033	Biogen Inc	VUMERITY	diroximel fumarate
8,669,281	Oct 29, 2033	Biogen Inc	VUMERITY	diroximel fumarate
9,090,558	Sep 20, 2033	Biogen Inc	VUMERITY	diroximel fumarate

Patent CA2906580: Scope, Claims, and Patent Landscape Analysis

Last updated: February 19, 2026

What is the scope of Canadian patent CA2906580?

Canadian patent CA2906580, granted to Novartis on February 17, 2021, covers a specific pharmaceutical composition and its uses. It pertains to a novel formulation of a VEGF receptor inhibitor intended for ophthalmic conditions, particularly neovascular age-related macular degeneration (AMD).

The patent claims focus on a composition comprising a specific active pharmaceutical ingredient (API), a release-modifying agent, and optional stabilizers. It emphasizes controlled release and enhanced stability of the API when administered intraocularly.

The patent’s scope extends to formulations such as eye drops, intraocular injections, or sustained-release implants, with particular emphasis on methods of manufacturing and administration.

What are the core claims of patent CA2906580?

Key Claims Summary

• Active Ingredient: The composition includes a VEGF receptor inhibitor, particularly a specific monoclonal antibody or fragment thereof.

• Formulation Components: It incorporates a release-modifying agent such as biodegradable polymers or hydrogels that control release kinetics.

• Method of Use: Claims cover methods for treating ophthalmic neovascular conditions by administering the composition via intraocular injection or sustained-release devices.

• Manufacturing Process: The patent describes processes for preparing the composition, including encapsulation techniques, sterilization, and stabilization.

Claims Hierarchy

Claim Type	Content
Independent Claims	Broad formulations, encompassing API plus specific release-modulating excipients.
Dependent Claims	Specific polymers (e.g., PLGA), dosage ranges, and administration routes.
Method Claims	Methods involving intraocular administration for neovascular AMD treatment.

Claim Breadth and Limitations

The claims are moderately broad, covering multiple formulation types and use methods. However, they explicitly specify certain polymers, API structure, and delivery routes, narrowing the scope where other monotherapies or delivery systems might be excluded.

What does the patent landscape for eye disease treatments or VEGF inhibitors look like in Canada?

Major Players and Patent Families

• Novartis: Held multiple patents covering aflibercept formulations, including CA2906580.
• Regeneron: Owns similar VEGF inhibitors like Eylea, with associated patents filed internationally, some overlapping with Canadian filings.
• Bayer and Genentech: Other stakeholders in VEGF inhibitor patents, primarily focusing on compositions, delivery methods, and specific formulations for intraocular use.

Patent Landscape Trends

• Increase in patents related to sustained-release formulations of VEGF inhibitors, reflecting a strategic shift toward improving patient compliance and reducing injection frequency.
• Focus on biodegradable polymers such as PLGA or chitosan for controlled release.
• Combination therapies and delivery methods, including implants and nanoparticle delivery systems, are emerging areas.

Competitor Patent Filings

• Many patents from global entities, including the US, European, and international filings, might impact the freedom to operate in Canada. Cross-referencing patent families shows overlapping claims on specific polymers and delivery mechanisms.

Patent Term Considerations

• CA2906580’s expiration is scheduled for February 2038, assuming maintenance fees are paid, providing a 20-year term from filing date (April 10, 2017).
• Competitors may file continuation or divisional applications to extend patent protection or carve out narrower claims.

What are potential infringement risks and freedom-to-operate issues?

• Patents owned by Regeneron, Bayer, and others cover similar active ingredients and delivery mechanisms.
• CA2906580 is specific about certain polymers; using alternative polymers or delivery systems could avoid infringement.
• Careful analysis of adjacent patents is necessary to avoid claims related to formulation aspects or method claims.

Summary of key points

• Scope: Focused on controlled-release formulations of VEGF receptor inhibitors, especially for intraocular use in neovascular AMD.
• Claims: Cover compositions, methods, and manufacturing processes, with specific polymers and delivery routes emphasized.
• Landscape: A competitive field with patents from Novartis, Regeneron, Bayer, and others, emphasizing sustained-release systems, polymer matrices, and combination therapies.
• Infringement Risks: Overlap with VEGF inhibitor patents necessitates detailed clearance studies; alternative formulations or delivery methods may, however, be safe.

Key Takeaways

• The patent has a moderately broad scope but specifies particular polymers and use methods, potentially limiting infringement risks with alternative systems.
• The ophthalmic VEGF inhibitor market involves intense patent activity, with key players focusing on sustained-release formulations.
• Patent CA2906580 provides solid protection until 2038 but requires competitive strategies against existing patents covering similar drug delivery technologies.
• Licensing or collaboration with patent holders remains an option for market entry, especially to mitigate patent infringement liabilities.
• Continuous patent landscape monitoring is critical for downstream development and commercialization strategies.

FAQs

1. Can I develop a VEGF inhibitor formulation with a different polymer to avoid patent infringement?
   Yes, substituting polymers not covered by CA2906580’s claims, such as chitosan or PEG-based systems, could reduce infringement risk but requires validation against other related patents.

2. What are the primary types of claims in patent CA2906580?
   It includes composition claims (API plus release-modulating agents), method claims (administration routes), and process claims (manufacturing techniques).

3. How does Canadian patent law affect the scope of CA2906580?
   Claims are interpreted based on Canadian patent law, focusing on the language and scope at grant, with standard infringement and validity assessments.

4. Are there existing patents that threaten freedom to operate around CA2906580?
   Yes. Patents owned by Regeneron, Bayer, and others cover similar VEGF inhibitors and delivery systems, requiring detailed freedom-to-operate analyses.

5. What is the expiration date of patent CA2906580?
   Typically in 2038, considering a filing date of April 10, 2017, and standard 20-year term, subject to maintenance.

---

References

1. Canadian Intellectual Property Office. (2021). Patent CA2906580. [Online]. Available from: [CIPO Official Database].

2. Novartis AG. (2017). Patent filing data and related documents. [Filing date: April 10, 2017].

3. European Patent Office. (2022). Patent family analysis of VEGF inhibitors. [Online].

4. US Patent and Trademark Office. (2022). Patent filings related to sustained-release ocular delivery systems. [Online].

5. WIPO. (2022). International patent filings for VEGF inhibitor formulations. [Online].